Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
08.06.2026 02:48
Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. See why REGN is a Buy.
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
08.06.2026 02:48
Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. See why REGN is a Buy.
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
05.06.2026 18:22
Regeneron Pharmaceuticals (REGN) has been back in focus after expanding its cancer therapy partnership with CytomX Therapeutics, a deal with up to $4b in potential milestones, alongside highly favorable Lynozyfic trial results in light chain amyloidosis. See our latest analysis for Regeneron Pharmaceuticals. Despite the Oncology headlines, the stock’s recent momentum has cooled, with the 30 day share price return down 10.47% and the 90 day share price return down 17.26%, even as the 1 year...
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
05.06.2026 14:24
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Parabilis eyes $475m IPO to push lead asset into Phase III
05.06.2026 10:54
The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours.
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
04.06.2026 11:00
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needsTARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026. These include the American Diabetes Association (ADA) 86th Scientif
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
04.06.2026 09:21
The partnership brings together CytomX’s biologic masking technology and Regeneron’s expertise in bispecific antibodies.
Why Regeneron (REGN) Stock Is Trading Up Today
04.06.2026 00:31
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy collaboration and reported positive clinical trial data for one of its treatments.
Are Options Traders Betting on a Big Move in Regeneron Stock?
02.06.2026 13:25
Investors need to pay close attention to REGN stock based on the movements in the options market lately.
Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application
31.05.2026 08:23
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On May 22, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application for Otarmeni, an in vivo adeno-associated virus vector-based gene therapy for biallelic OTOF variant-associated […]
Regeneron And Parabilis Target Undruggable Proteins As Valuation Draws Interest
28.05.2026 15:04
Regeneron Pharmaceuticals (NasdaqGS:REGN) has entered a research collaboration with Parabilis Medicines to develop therapeutics for previously "undruggable" proteins. The alliance uses Parabilis' Helicon peptide platform for up to five initial targets, with scope for milestone payments and potential expansion to more programs. The partnership focuses on challenging intracellular proteins and aims to broaden Regeneron's discovery capabilities beyond its existing technology platforms. For...
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins
25.05.2026 19:54
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Regeneron Pharmaceuticals entered into a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis’ Helicon peptide platform. The partnership will focus on creating Helicons (stabilized, cell-penetrant alpha-helical peptides) that can be used as […]
Regeneron R&D Updates Test Market View On Long Term Pipeline Value
24.05.2026 06:08
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive early-stage trial results for Lynozyfic in systemic AL amyloidosis, with high response rates and signs of organ function improvement. The European Medicines Agency accepted Otarmeni, a gene therapy candidate for OTOF-related hearing loss, for accelerated review as a potential first treatment of its kind in Europe. These twin updates arrive at a time when NasdaqGS:REGN is trading at $638.88, with the stock down 8.5% over the past...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22.05.2026 11:00
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
21.05.2026 13:12
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was among the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation. Cramer highlighted the company’s unsuccessful trial, as he remarked: Finally, there’s Regeneron, which got blasted by a poor result on a metastatic melanoma cancer trial. I, along with many others, thought that this trial […]
Apogee Therapeutics: Targeting Atopic Dermatitis
21.05.2026 11:53
Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.
ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospects
20.05.2026 17:54
Failure of AERIFY-2 to show clear benefit in COPD places itepekimab on the backfoot against AstraZeneca’s tozorakimab.
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
20.05.2026 11:58
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
19.05.2026 12:11
Earlier in May 2026, Regeneron Pharmaceuticals reported that its Phase 3 trial of fianlimab plus cemiplimab in first-line unresectable or metastatic melanoma failed to achieve statistically significant improvement in progression-free survival versus pembrolizumab, although no new safety issues emerged. This trial miss has already prompted legal scrutiny of Regeneron’s leadership and intensified concerns about the company’s oncology pipeline and future revenue mix. We’ll now examine how...
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
19.05.2026 10:16
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.